Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Ashton Thomas Securities LLC

Ashton Thomas Securities LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 810 shares of the biopharmaceutical company’s stock after purchasing an additional 20 shares during the period. Ashton Thomas Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $577,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Great Valley Advisor Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 5.0% in the third quarter. Great Valley Advisor Group Inc. now owns 442 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 21 shares in the last quarter. Cerity Partners LLC boosted its position in Regeneron Pharmaceuticals by 18.5% during the 3rd quarter. Cerity Partners LLC now owns 15,548 shares of the biopharmaceutical company’s stock worth $16,344,000 after purchasing an additional 2,423 shares during the period. Kingsview Wealth Management LLC raised its position in Regeneron Pharmaceuticals by 2.6% in the third quarter. Kingsview Wealth Management LLC now owns 860 shares of the biopharmaceutical company’s stock valued at $904,000 after purchasing an additional 22 shares during the period. Larson Financial Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 127.3% during the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 28 shares in the last quarter. Finally, Independent Advisor Alliance acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $231,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on REGN. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Citigroup cut their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Down 4.1 %

REGN stock opened at $634.14 on Wednesday. The stock has a market cap of $69.33 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm’s 50-day simple moving average is $687.18 and its 200 day simple moving average is $806.20. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $633.10 and a fifty-two week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.56%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.